AI in cancer drug development at ENA 2026

Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website

6 organizations at ENA 2026 present work in artificial intelligence in cancer drug development: 2 cancer centres and hospitals, 2 CROs and suppliers, 1 drug developer and 1 university or institute. Between them they bring 27 presentations to the program. Most represented: MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center and Calico Life Sciences. As of Oct 13, 2026.

All 254 organizations at ENA 2026 →

Showing 1–6 of 6 organizations

Organization	ENA 2026 Attendance
MD Anderson Cancer Center Houston, Texas
mdanderson.org Cancer centres & hospitals University of Texas cancer centre for patient care, research and early-phase clinical trials.	Session Wed Nov 18 4:15–5:45pm Workshop 2: Radiopharmaceuticals ADCs & radioligands Talk Wed Nov 18 4:55–5:15pm Part of Workshop 2: Radiopharmaceuticals Translating Radiopharmaceutical Innovation from Bench to Bedside ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates Translational validation of uPARAP (MRC2) as an antibody–drug conjugate target in osteosarcoma patient-derived xenograft models ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates Preliminary phase 1 results from AVENTINE-1, a phase 1/2 study of AVZO-1418, an EGFR-HER3 bispecific antibody-drug conjugate (BsADC) for the treatment of patients with locally advanced or metastatic solid tumors ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates Population pharmacokinetics (popPK) and exposure-response analyses of sacituzumab tirumotecan (sac-TMT) antibody-drug conjugate (ADC) in participants (pts) with advanced solid tumors ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Drug Resistance and Modifiers TROP2 Predicts Response to TUSC2 Gene Therapy (Quaratusugene Ozeplasmid) and Its Modulation Sensitizes Non-Small Cell Lung Cancer to Treatment Targeted agents Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Translational Studies Targeting the PI4K2A lysosomal pathway is a promising approach for lung cancer therapy Biomarkers Talk Thu Nov 19 10–10:10am Part of Plenary Session 3: Proffered Papers Phase 1 trial and translational study of the glutaminase-1 (GLS1) inhibitor IACS-6274 in combination with bevacizumab and paclitaxel in patients with advanced ovarian cancer Early clinical · Targeted agents Session Thu Nov 19 2–2:30pm Posters in the Spotlight, session 1 Session Thu Nov 19 3–4:30pm Workshop 3: End-to-End Early Clinical Development Through AI AI · Early clinical Session Thu Nov 19 3–4:30pm Workshop 4: Next-Generation Precision Oncology: Progress, Pitfalls and Promise Genomics Talk Thu Nov 19 3:20–3:40pm Part of Workshop 3: End-to-End Early Clinical Development Through AI Radiology - Digital twins and multiomics AI · Early clinical Talk Thu Nov 19 3:40–4pm Part of Workshop 4: Next-Generation Precision Oncology: Progress, Pitfalls and Promise Rewiring the Cell Cycle: Early Clinical Insights from Next-Generation Cyclin and CDK Targeting Genomics Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Drug Delivery A Bayesian pharmacokinetics-integrated Phase I–II design to optimize dose-schedule regimes Drug design Talk Fri Nov 20 3–3:10pm Part of Plenary Session 7: Proffered papers Interim results from the ﬁrst-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051) Early clinical · Targeted agents Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Combination Therapies Discovery of novel combination strategies to target SWI/SNF mutant lung cancers Targeted agents
Memorial Sloan Kettering Cancer Center New York, NY
mskcc.org Cancer centres & hospitals Cancer treatment and research centre with clinical, laboratory and computational research programmes.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Drug Resistance and Modifiers A super glue to trap wild-type and mutant variants of the ARAF:MEK1 complex Targeted agents Talk Thu Nov 19 8–8:25am Part of Plenary Session 2: RAS pathway: "Targeting RAS - What's Next?" Brief clinical overview, mechanistic insights into resistance and RBD mutation studies Targeted agents Talk Thu Nov 19 4–4:20pm Part of Workshop 3: End-to-End Early Clinical Development Through AI Therapeutic selection – drug design and protein folding AI · Early clinical Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: New agents for paediatric oncology Safety and efficacy of autologous tumor infiltrating lymphocyte therapy in pediatric and adolescent patients with immune checkpoint inhibitor-refractory metastatic melanoma: Results from a phase I clinical trial Targeted agents Talk Fri Nov 20 12:15–12:25pm Part of Plenary Session 6: Proffered papers ARV-806, a PROTAC KRAS G12D Degrader, in Patients With KRAS G12D–Mutated Advanced Solid Tumors: Preliminary Phase 1 Results Drug design · Early clinical
Calico Life Sciences South San Francisco, CA
calicolabs.com Biotech Alphabet-founded company researching the biology of ageing and developing drugs for age-related diseases, including cancer.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Artificial Intelligence Systematic Prioritization of Oncology Targets (SPOT): A Multi-Agent Artificial Intelligence Platform for Evidence-Based Drug Target Prioritization AI Talk Thu Nov 19 4:45–4:50pm Part of Posters in the Spotlight, session 2 The Integrated Stress Response (ISR) promotes an immunosuppressive tumor microenvironment which is targetable with 2BAct Immuno-oncology
Concr London, UK
concr.co Tools, data & diagnostics Builds AI digital-twin models of cancer patients to predict treatment response for trials and drug development.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Artificial Intelligence Multi-modal Digital Twin Model Outperforms Conventional Biomarker Stratification in Pancreatic Cancer AI Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Artificial Intelligence Multimodal Digital Twins Predict Chemotherapy Backbone Response to Uncover Immunotherapy Benefit in TNBC AI
BioLizard Ghent, Belgium
lizard.bio Tools, data & diagnostics Bioinformatics and AI partner that analyses omics, spatial and clinical data for life science companies.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Artificial Intelligence A Data-Driven Landscape Analysis of Novel Targets for CAR-T Cell Therapy in Acute Myeloid Leukemia AI
Techna Institute Toronto, Canada
technainstitute.com Universities & institutes University Health Network institute developing data science, engineering and health informatics technology for patient care.	Talk Thu Nov 19 3–3:20pm Part of Workshop 3: End-to-End Early Clinical Development Through AI Medical Oncology – AI applications for clinical use AI · Early clinical